Light-activated CRISPR/dCas9 nanomedicine for programmable control of renal fibrosis.
It is argued that the most defensible therapeutic objective is not permanent genome editing or autonomous organ regeneration, but spatially confined, temporally limited, and reversible regulation of validated fibrotic or protective gene programs using CRISPRa, CRISPRi, or dCas9-based epigenome editors.
B. Taha, Ali J. Addie, A. Haider et al.
· Journal of Photochemistry an... · 0 citations